Overview

• Synt-101, developed by Syntis Bio, mimics the effects of gastric bypass surgery by creating a temporary coating in the upper intestine to suppress appetite and reduce calorie absorption.
• Initial human pilot trials on nine participants demonstrated the pill’s safety and showed reduced hunger signals through elevated leptin and lower ghrelin levels.
• The pill is designed to be taken daily, integrates with the gut lining, and is naturally excreted within 24 hours, offering a reversible and non-invasive alternative to surgery.
• Developers anticipate minimal to no side effects as the pill does not enter the bloodstream, unlike GLP-1 weight-loss injections, which can cause significant side effects.
• Syntis Bio aims to establish Synt-101 as a leading weight management option, with larger trials planned to confirm sustained weight-loss outcomes and safety.